All In MedTech

FDA Clearance Tracker · P200026

Abre Venous Self-expanding Stent System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Oct 21, 2020 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 21, 2020

Approved

Time to decision

177 days

Received Apr 27, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P200026
Device name
Abre Venous Self-expanding Stent System
Applicant location
Plymouth, MN
Received
Apr 27, 2020
Decided
Oct 21, 2020
Decision
Approved
Supplements
20 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QAN

FDA's approval statement

As written in FDA's record.

Approval for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QAN. The earliest in FDA's data is P180037, decided Mar 13, 2019.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.